Keyword: Xolair

Novartis

4. Novartis

To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.

5. Xolair

While a key Xolair patent expires in 2018, it's unclear when any biosimilars could reach the market.